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1. ABSTRACT 
AIMS: Empagliflozin (EMPA) is a potent inhibitor of the renal sodium-glucose 
cotransporter 2 (SGLT2) and an effective treatment for type-2 diabetes. In patients 
with diabetes and heart failure, EMPA has cardioprotective effects independent of 
improved glycaemic control, despite SGLT2 not being expressed in the heart. A 
number of non-canonical mechanisms have been proposed to explain these cardiac 
effects, most notably an inhibitory action on cardiac Na+/H+ exchanger 1 (NHE1), 
causing a reduction in intracellular [Na+] ([Na+]i). However, at resting intracellular pH 
(pHi), NHE1 activity is very low and its pharmacological inhibition is not expected to 
meaningfully alter steady-state [Na+]i. We re-evaluate this putative EMPA target by 
measuring cardiac NHE1 activity. 
METHODS AND RESULTS: The effect of EMPA on NHE1 activity was tested 
in isolated rat ventricular cardiomyocytes from measurements of pHi recovery 
following an ammonium pre-pulse manoeuvre, using cSNARF1 fluorescence imaging. 
Whereas 10 µM cariporide produced near-complete inhibition, there was no evidence 
for NHE1 inhibition with EMPA treatment (1, 3, 10 or 30 µM). Intracellular acidification 
by acetate-superfusion evoked NHE1 activity and raised [Na+]i, reported by sodium 
binding benzofuran isophthalate (SBFI) fluorescence, but EMPA did not ablate this 
rise. EMPA (10 µM) also had no significant effect on the rate of cytoplasmic [Na+]i-rise 
upon superfusion of Na+-depleted cells with Na+-containing buffers. In Langendorff-
perfused mouse, rat and guinea pig hearts, EMPA did not affect [Na+]i at baseline nor 
pHi recovery following acute acidosis, as measured by 23Na triple quantum filtered 
NMR and 31P NMR, respectively.  
CONCLUSIONS: Our findings indicate that cardiac NHE1 activity is not 
inhibited by EMPA (or other SGLT2i’s) and EMPA has no effect on [Na+]i over a wide 
range of concentrations, including the therapeutic dose. Thus, the beneficial effects of 
SGLT2i’s in failing hearts should not be interpreted in terms of actions on myocardial 
NHE1 or intracellular [Na+]. 
TRANSLATIONAL PERSPECTIVE: Heart failure remains a huge clinical 
burden. Clinical trials of SGLT2 inhibitors in patients with diabetes and heart failure 
have reported highly significant cardiovascular benefit that appears independent of 
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improved glycaemic control. As SGLT2 is not expressed in the heart, the mechanism 
by which SGLT2 inhibitors are cardioprotective remains unknown. Understanding this 
mechanism is clearly essential as the use of SGLT2 inhibitors in non-diabetics is 
increasing and a better understanding may allow refinement of therapeutic 
approaches in both HFpEF and HFrEF. One suggested mechanism that has received 
significant attention, inhibition of cardiac Na+/H+ exchanger, is investigated here. 
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2. INTRODUCTION 
Empagliflozin (EMPA), an inhibitor of renal sodium-glucose cotransporter 2 
(SGLT2), is used clinically in the treatment of type-2 diabetes.1 Recent clinical trials 
have however, described an unexpected beneficial cardiovascular effect associated 
with EMPA, notably a reduction in heart failure-related hospitalization independent of 
improved glycaemic control.2 These clinical observations are supported by preclinical 
studies in animal models, with or without background diabetes, showing that heart 
failure and pathological cardiac remodelling are alleviated by EMPA.3–5 These 
cardioprotective effects are observed despite cardiomyocytes not expressing 
SGLT2,6–8 leading to suggestions that SGLT2 inhibitors (SGLT2i) may have non-
canonical actions on other proteins in the heart. 
Using isolated cardiac ventricular myocytes, two previous studies reported a 
strong inhibitory class effect of SGLT2i (including EMPA) on cardiac Na+/H+ 
exchanger-1 (NHE1), a Na+-driven pH-regulating membrane protein.9,10 In these 
studies, SGLT2i were reported to reduce intracellular [Na+] and [Ca2+] as a result of 
NHE1 inhibition. Given that elevation of [Na+]i is causally associated with the 
pathophysiology of heart failure,11,12 the authors suggested that the non-canonical 
efficacy of SGLT2i relates to their [Na+]i-lowering effect, leading to reduced Ca-
overload and hence protection against adverse cardiac remodelling.13,14 
There are, however, concerns about the feasibility of this hypothesis, based on 
the properties of NHE1. As the dominant isoform present in myocardium, NHE1 is 
steeply activated by a fall in intracellular pH (pHi).15 While intracellular acidosis 
activates NHE1 and drives a recovery of pHi and intracellular Na+-loading, the activity 
of this transporter near resting pHi (~7.2) is very low (<1 mmol/min),15 and therefore 
inhibiting this basal flux would not be expected to meaningfully affect steady-state 
myocyte [Na+]i while the Na+/K+ ATPase remains functional. In fact, numerous reports 
in the literature have shown that NHE1 inhibition in the normoxic myocardium with 
drugs, such as cariporide, is without effect on intracellular [Na+].16–18 The suggestion 
that SGLT2i reduce intracellular [Na+] via NHE1 inhibition under physiological 
conditions, in healthy normoxic myocytes or in a beating heart, is therefore surprising 
and merits further validation, particularly since this idea is gaining traction.19–22  
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In the present work, we evaluate the inhibitory effects of EMPA on cardiac 
NHE1 and further investigate its actions on cardiac Na+ handling in isolated cardiac 
myocytes and Langendorff-perfused hearts. Our findings show that EMPA, contrary to 
previously published reports, is not a direct inhibitor of cardiac NHE1 and does not 
reduce intracellular [Na+].  D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa323/5949073 by guest on 06 N
ovem
ber 2020
 6 
3. METHODS 
 Approvals for animal work. Animal procedures were performed in compliance 
with the guidelines from Directive 2010/63/EU of the European Parliament on the 
protection of animals used for scientific purposes, Home Office Guidance on the 
Operation of the Animals (Scientific Procedures) Act of 1986 and the King’s College 
London and the University of Oxford institutional guidelines. Wistar rats, CD1 mice 
and Dunkin-Hartley guinea pigs were purchased through Envigo. Sprague Dawley rats 
were purchased through Charles River. Animals were killed humanely by a Schedule 
1 method and death confirmed by exsanguination. 
 Drugs. EMPA was obtained independently from Boehringer Ingelheim2,20,23 
and from MedChemExpress (MCE),9,10,24,25 and referred to herein as EMPA and 
mEMPA, respectively. Dapagliflozin (DAPA) and canagliflozin (CANA) were obtained 
from MCE. Cariporide, a selective NHE1 inhibitor, was obtained from Sanofi-Aventis. 
The structure and physical characteristics of EMPA were verified using high pressure 
liquid chromatography-mass spectrometry (HPLC-MS), 1D/2D NMR and circular 
dichroism (CD) spectroscopy. Therapeutically-relevant plasma concentrations of 
EMPA have been reported to be in the range ~200-700 nmoles/L with plasma protein 
binding of approximately 90%.26 To ensure we adequately cover or exceeded both the 
concentrations used in previously studies in vitro and the therapeutically-relevant 
concentrations, we have used concentrations ranging from 1-30 µM in DMSO (0.01% 
v/v, or 0.03% v/v in the case of 30 µM EMPA). 
 Cardiomyocyte isolation. Male Sprague-Dawley (300-325 g) rats, used for 
fluorescence experiments, were sacrificed by a method designated Schedule 1 by the 
Animals (Scientific Procedures) Act of 1986 (concussion of the brain by striking the 
cranium followed by cervical dislocation). Male Wistar (325-350 g) rats, used for 
electrophysiology experiments, were terminally anaesthetized and heparinised with 60 
mg/kg sodium pentobarbitone and 100U sodium heparin, intraperitoneally. Ventricular 
myocytes were isolated from Langendorff-perfused hearts using a combination of 
mechanical and enzymatic (1 mg/mL Type II Collagenase, Worthington Biochemical 
Corporation; 0.025 mg/mL Type XIV Protease, Sigma-Aldrich/Merck) dispersion. For 
cells isolated for fluorescence experiments, the isolation solution contained (in mM): 
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120 NaCl, 4 KCl, 1.2 MgCl2, 10 HEPES, 1 NaH2PO4, 11 glucose, 20 taurine, 2.5 
pyruvic acid, (pH 7.4 with NaOH at 37°C). For cells isolated for electrophysiology, the 
isolation solution contained (in mM): 130 NaCl, 4.5 MgCl2, 4.2 HEPES, 0.4 NaH2PO4, 
10 glucose, 20 taurine, 10 creatine (pH 7.4 with NaOH at 37°C) and bubbled with 100% 
O2. Isolated myocytes were introduced to calcium-containing solution in a step-wise 
manner to reach a final concentration of 1 mM. Only quiescent, Ca2+-tolerant myocytes 
that were rod-shaped with clear striations, were selected for experiments.  
Cell culture. HCT116 cells (kind gift from Professor Walter Bodmer, University 
of Oxford, UK) were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 44 mM bicarbonate, 10% fetal calf serum, and 1% pen-strep and 
maintained at 37ºC and 5% CO2. Stably transfected HEK293-hSGLT2 cells were 
obtained from Boehringer Ingelheim. Cells were grown and maintained in DMEM at 
37ºC and 5% CO2. 
Fluorescence imaging. For pH measurements, primary cardiomyocytes or 
HCT116 cells were loaded with 17.6 µM cSNARF-1 (AM-ester) at room temperature 
for 6 min, plated onto a poly-L-lysine coated Perspex chamber mounted on a Zeiss 
LSM 600 confocal system. Excitation was delivered by 555 nm laser and emission 
was collected simultaneously at 580 nm and 640 nm. For intracellular sodium ion 
concentration ([Na+]i) measurements, primary cardiomyocytes were loaded with 17.7 
µM SBFI (AM-ester with 0.1% Pluronic) at room temperature for 2 h, plated onto a 
poly-L-lysine coated Perspex chamber mounted on an Olympus IX73 microscope. 
Excitation alternated between 365 nm for 100 ms and 385 nm for 200 ms, emission 
was collected at > 500 nm. 
Superfusion. All superfusion experiments were performed at 37C achieved 
through a feedback heater. Dye-loaded cells were superfused in Tyrode’s buffer 
containing (in mM): 135 NaCl, 4.5 KCl, 1 MgCl2, 20 HEPES, 11 glucose, and 1 CaCl2 
(pH 7.4 with NaOH at 37C; and, in the case of SBFI, 2 mM probenecid dissolved in 
NaOH). For the ammonium pre-pulse protocol, cells were stabilised in Tyrode’s buffer 
for 5 min, perfused in 15 mM NH4+Cl (NaCl reduced to maintain osmolarity) for 6 min, 
followed by return to Tyrode’s buffer (the recovery period). Washout of NH4+ produces 
a rapid rebound acidification which triggers NHE1 activity. Drugs were included in both 
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NH4Cl-containing buffer and during the recovery period. For the acetate protocol, cells 
were stabilised in Tyrode’s buffer for 5 min, pre-treated in drug (or DMSO) for 10 min, 
then perfused in 80 mM acetate for 4 min (NaCl reduced to maintain osmolarity). For 
0Na0Ca protocol, cells were stabilised in Ca-free Tyrode’s buffer for 4 min, superfused 
in Na-free/Ca-free buffer (in mM: 140 N-methyl-D-glucamine, 4.5 KCl, 1 MgCl, 20 
HEPES, 11 glucose, and 0.5 EGTA; pH 7.4 with HCl at 37C) for 8 min, then returned 
to Ca-free buffer containing 30 µM cariporide for 8 min. Drugs were included 
throughout the protocol.  
Electrophysiology. Na+/K+ pump current was measured using whole-cell 
voltage clamping, using the perforated patch technique to minimise intracellular 
dialysis and at 35°C.24 Rat ventricular cardiac myocytes were plated onto laminin 
(L2020 Sigma-Aldrich) coated coverslips and Na+/K+ pump current measured via 
borosilicate glass microelectrodes (1.5-2 MΩ). The pipette filling solution contained (in 
mM): 103 Cs methanesulfonate, 25 Na methanesulfonate, 20 CsCl, 10 HEPES, 1 
CaCl2, 1 MgCl2 (pH=7.3 with CsOH at 35°C). Before the experiment, amphotericin B 
(A4888 Sigma-Aldrich) was freshly dissolved in DMSO and added to the pipette 
solution (final concentration of ~240 µg/ml). Whole-cell currents were monitored using 
an Axopatch 200B amplifier, Digidata 1322A DAQ and pClamp 9.2 software 
(Molecular Devices, Sunnyvale, CA). Bath and pipette solutions were designed to 
minimise contamination with other currents. The bath solution contained (in mM): 140 
NaCl, 5 KCl, 1 MgCl2, 2 NiCl2, 1 BaCl2, 10 glucose, 10 HEPES, (pH 7.3 with NaOH at 
35°C). In the majority of experiments, the membrane potential was clamped at 0 mV. 
Current-voltage (I/V) relationships were recorded during a 10 s ramp pulse (13 mV/sec) 
from +40 to -90 mV. Na+/K+ pump current was calculated after subtracting the current 
recorded in external K+-free solution from that recorded in the presence of 5 mM of 
K+. Na+/K+ pump current at 0 mV was low-pass filtered at 100 Hz and sampled at 200 
Hz. During ramp I/V curves, currents were low-pass filtered at 1 kHz and sampled at 
2 kHz. In order to average between cells, and provide mean ± error bars, data were 
'binned' along the X-axis into 'bins' each containing 800 samples with each bin 
representing an average of 5.2mV. 
Glucose uptake assay. One day prior to experiments, cells over-expressing 
the human SGLT2 transporter (HEK293-hGSLT2) were seeded to 75% confluency in 
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a 96-well plate. Cells were washed in 1x PBS and glucose starved for 30 min in 
glucose-free DMEM and subsequently treated with either 5 or 50 nM EMPA, DAPA or 
CANA for 15 min. Glucose uptake assay was performed using the Promega Glucose 
Uptake-Glo Assay following manufacturer’s instructions. The assay measures 
luciferase bioluminenscence following uptake of 2-deoxyglucose into cells. 
Luminescence was recorded using the Promega GloMax Multi Detection System 
microplate reader.  
 Langendorff perfusion. Hearts were rapidly excised and cannulated via the 
aorta and perfused at 37C at constant pressure of 80 mmHg (60 mmHg for guinea 
pig). Perfusion buffer was either Krebs-Henseleit buffer (KHB) containing (in mM): 118 
NaCl, 5.9 KCl, 1.16 MgSO4, 25 NaHCO3, 0.48 EDTA, 11 glucose, 2.2 CaCl2 and 
bubbled with 5% CO2/95% O2 or modified Tyrode’s buffer containing (in mM): 135 
NaCl, 4.5 KCl, 1.16 MgCl2, 10 HEPES, 0.48 EDTA, 11 glucose, 2.2 CaCl2 (pH 7.4 with 
NaOH at 37C) and bubbled with 100% O2. For the Na-acetate protocol, Tyrode’s 
buffer was modified to 10 mM Na-acetate and 125 mM NaCl. Hearts were subject to 
one of two protocols. Protocol 1: 20 min stabilisation in KHB then 15 min KHB with 1 
µM EMPA, DMSO (0.01% v/v), or 10 µM cariporide. Protocol 2: 10 min stabilisation in 
KHB, 10 min stabilisation in Tyrode’s buffer, 15 min in Tyrode’s buffer containing 1 or 
10 µM EMPA, DMSO or 10 µM cariporide, then 40 min in 10 mM Na-acetate buffer 
supplemented with drug. Cardiac function was monitored throughout the protocol via 
a balloon inserted into the left ventricle and monitored on LabChart. The Langendorff 
rig was modified for NMR as described previously.27 
 NMR spectroscopy. 31P and 23Na NMR spectra was acquired on the Bruker 
Avance III 400 MHz Spectrometer 9.4T vertical-bore magnet. For mouse experiments, 
10 mm dual tuned 31P/1H and 15 mm single tuned 23Na coils were used. For rat, 15 
mm dual tuned 31P/1H and 23Na/1H coils were used. For guinea pig, a 30 mm dual 
tuned 31P/23Na microimaging coil was used. Spectra were acquired and analysed 
using TopSpin 3.7pl software. For every heart, shimming was carried out on either the 
1H channel or the 23Na channel. Time-resolved 23Na spectra were acquired using 
multiple quantum filtered (MQF) experiments to separate intracellular and extracellular 
contribution to the 23Na signals, as described previously.27 Interleaved triple quantum 
filtered (TQF) and double quantum filtered (DQF) NMR acquisitions, consisting of 192 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa323/5949073 by guest on 06 N
ovem
ber 2020
 10 
scans and an experimental duration of 1 min (252 scans and 2 min for mouse), were 
recorded throughout the entire protocol. 31P spectra were acquired with a 60 flip angle, 
64 scans and a total experiment duration of 5 min for a single spectrum. 
Statistics. Data are reported as mean ± SEM. For cardiomyocyte-based 
experiments, statistical testing was performed on number of cells. Control (DMSO) 
recordings were performed on each day to match data for the effects of drug. 
Hierarchical analysis was performed to seek evidence for clustering. Non-hierarchical 
tests were deemed suitable for datasets with small clustering (<15%).28  To compare 
between pH-flux relationships and between time courses, a 2-way ANOVA followed 
by Sidak’s multiple comparison’s test was used to determine statistical significance. 
To compare steady-state pH, a 1-way ANOVA followed by Tukey’s multiple 
comparison’s test was used to determine statistical significance. To compare pHi 
recovery time course, LVDP and coronary flow in Langendorff perfused hearts, a 2-
way ANOVA followed by Tukey’s multiple comparison’s test was used to determine 
statistical significance. For all other assays, two-tail, unpaired student’s t-test was 
used to compare SGLT2i group mean with the control (DMSO) group. * p<0.05, ** 
p<0.01, ***p< 0.001, ****p< 0.0001. Data analysis was carried out in a blinded manner. 
For experiments on single cells, repeats are noted as n = number of animals or n= 
number of cells from number of animals from which cells were isolated. 
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4. RESULTS 
EMPA does not inhibit NHE1 in isolated cardiomyocytes 
EMPA, sourced from two independent manufacturers (mEMPA, EMPA), was 
first tested for purity by 1D 1H and 13C NMR acquired at 800 MHz, circular dichroism 
and HPLC-MS (Figure S1). These assays showed that both sources supplied the 
same chemical compound (Fig S1A, C and D) in a single enantiomeric form (Fig S1B), 
with impurities less than 1% determined by NMR (w/w). Both EMPA and mEMPA 
inhibited glucose uptake in a dose-dependent manner in HEK293 cells overexpressing 
SGLT2, thus verifying that the drugs were active compounds (Figure S2). 
Having validated the chemical identity and purity of EMPA, the effects of EMPA 
on NHE1 activity was investigated in isolated cardiac myocytes using fluorescence 
measurements on cells loaded with the pH-reporter cSNARF1 (Figure 1). The 
inhibitory effects of compounds on NHE1 is resolved best under conditions that 
normally evoke large NHE1 fluxes, such as in response to an intracellular acidosis. 
Cells were acid-loaded by means of an ammonium pre-pulse solution manoeuvre. 
Upon ammonium washout, the cell abruptly acidifies as intracellular NH4+ 
deprotonates to membrane-permeable NH3 which then rapidly escapes across the 
membrane leaving H+ ions in the cytoplasm (the acid-load). To inactivate HCO3--
dependent acid-extruders, myocytes were superfused in CO2/bicarbonate-free 
HEPES-buffered Tyrode’s buffer. The time course of pHi recovery provides a readout 
of NHE1 activity. In control cells, pHi recovered towards pHi 7.3 over a period of ~12 
min. Cariporide (10 µM), a potent and selective NHE1 inhibitor,29 substantially inhibited 
pHi recovery, explaining why pHi remained acidic during the measurement period 
(Figure 1A, C, E and G). Superfusion with buffers containing EMPA (1 or 10 µM) did 
not slow the rate of pHi recovery. From these recovery time-courses, transmembrane 
H+ flux was calculated and plotted as a function of pHi (Figure 1B, D, F and H). Briefly, 
flux is obtained by multiplying the rate of pHi recovery (dpHi/dt) and buffering capacity 
(dH/dpH) for rat myocytes determined in an earlier study.30 NHE1-mediated 
transmembrane H+ flux was unaffected by either mEMPA or EMPA, strongly arguing 
against any direct inhibitory actions on cardiac NHE1. This is visualised by plotting flux 
in the presence of EMPA versus flux at matching pHi recorded under drug-free 
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conditions (Figure 2A-E); the slope of this relationship, fitted from the origin, gives an 
estimate of NHE1 activity in the presence of drug across all pHi values tested. Given 
that neither EMPA nor mEMPA appeared to have an effect on NHE1 flux, data from 
both drugs at their respective concentrations were combined. For 1, 3, and 10 µM 
EMPA, the 95% confidence interval of the slope of the flux-flux relationship included 
1.0, i.e. no significant inhibition by EMPA (Figure 2F). At supra-therapeutical 
concentration of 30 µM EMPA (Figure 2D), the 95% confidence interval was 0.89-
0.96, i.e. a statistically significant inhibition, but the magnitude of this inhibitory effect 
was only 8% (compared to effects of cariporide (Figure 2E) where 10 µM inhibited flux 
by >80%). Interestingly, the steady-state pHi reached at the end of pHi recovery was 
significantly more alkaline, by 0.1 units, in 3 and 10 µM EMPA (Figure 2G). Whilst this 
observation is not consistent with NHE1 inhibition, a possible explanation for the small 
change in steady-state pHi is an inhibitory effect of EMPA on metabolic acid production 
or acid-loading transporters, such as Cl-/OH- exchange. 
Other SGLT2 inhibitors do not affect NHE1 flux 
Uthman et al (2018) reported that two other SGLT2i’s, dapagliflozin (DAPA) 
and canagliflozin (CANA), also inhibit NHE1.10 Given that in our hands EMPA did not 
affect NHE1 activity, we tested whether DAPA or CANA inhibit NHE1 in cardiac 
myocytes subjected to intracellular acidification via an ammonium pre-pulse 
manoeuvre. As seen with EMPA, neither of these SGLTi’s (10 µM) inhibited pHi 
recovery nor meaningfully reduce NHE1 flux (Figure S3). 
EMPA does not block flux carried by the human NHE1 protein 
Although EMPA did not inhibit NHE1 flux in isolated rat myocytes, subtle 
species-specific differences in NHE1 primary structure may affect the protein-EMPA 
interaction. To exclude a species-specific interaction, NHE1 activity was measured in 
HCT116 cells, which express the human isoform of NHE1, in the presence or absence 
of EMPA. Neither 1 nor 10 µM EMPA inhibited pHi recovery or NHE1 flux following 
intracellular acidification (Figure S4), suggesting that EMPA also does not inhibit the 
human isoform of NHE1.  
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EMPA does not affect cellular Na-handling in cardiomyocytes 
Another readout of NHE1 activity is [Na+]i measured by SBFI. Baseline [Na+]i 
was recorded and found to be unaffected by EMPA at neither 1 µM nor 10 µM (after 
15 mins pre-treatment in EMPA; Figure 3A). Similarly, 10 µM cariporide for 15 min 
had no significant effect on baseline [Na+]i. To drive an NHE1-dependent rise in [Na+]i, 
myocytes were superfused with 80 mM acetate in HEPES-buffered solution, which 
acidifies the cytoplasm and triggers NHE1 activity and subsequent intracellular sodium 
loading (Figure 3B). The acetate-evoked [Na+]i response was ablated by cariporide, 
revealing an acidification-induced pH-artefact of the dye (Figure S5). The presence of 
EMPA did not affect the slope of the [Na+]i rise compared to the control, consistent 
with results obtained with NHE1 interrogated using pHi as a readout of activity in 
Figure 1. The time courses presented in Figure 3B have been corrected for this pH-
dependence of SBFI ratio. 
NHE1 is one of a number of Na+-entry pathways into the myocyte, and it is 
plausible that EMPA may be affecting other transporters.31 To test this, myocytes 
loaded with SBFI were first perfused in Ca2+-free Tyrode’s buffer, then switched to 
buffer in which Na+ salts were replaced with N-methyl-D-glucosamine (Na+-free, Ca2+-
free Tyrode’s buffer, 0Na0Ca; Figure 3C). This manoeuvre depleted intracellular Na+, 
and the rate of this depletion is an approximate readout of Na+/K+ ATPase (NKA) 
activity. Next, cells were returned to Na+-containing superfusates supplemented with 
30 µM cariporide to allow Na+ entry by all routes, except for NHE1. EMPA (1 µM, 10 
µM) did not affect the time constant of Na+ repletion (Figure 3D), indicating that other 
Na entry routes are unlikely to be targets of EMPA. However, the rate of Na+-depletion 
was reduced by 10 µM EMPA (Figure 3E), suggesting a possible inhibition of NKA. 
Therefore, the activity of NKA was further probed using the perforated-patch voltage-
clamp technique in rat cardiac myocytes to measure NKA current (Figure 4). Pump 
current was not affected by 10 µM EMPA treatment over the physiological voltage 
range (Figure 4A, B).  
NKA current also provides another indirect index of [Na+]i. In these experiments, 
the perforated-patch method of voltage-clamping was used to prevent cell dialysis.32 
Under these conditions, NKA current is steeply dependent on the prevailing [Na+]i.33 
Figure 4C shows absolute pump current density measured in pA/pF. An EMPA-
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induced decline in [Na+]i would be expected to reduce NKA current density at 0 mV; 
however this was not observed, suggesting that EMPA did not lower [Na+]i with respect 
to baseline in these experiments. 
EMPA does not decrease intracellular [Na+] in Langendorff-perfused hearts 
Although EMPA had no effect on basal [Na+] in quiescent cardiomyocytes 
(Figure 2A) and two independent readouts of NHE1 activity in isolated myocytes 
(Figure 1, 2 and 3B), some actions may become apparent only in the intact beating 
heart. Langendorff-perfused rat hearts were treated with EMPA, and [Na+]i was 
measured using triple quantum filtered (TQF) NMR experiments.27 Following 20 min 
of stabilisation in either CO2/bicarbonate-buffered Krebs (KHB) buffer or 10 min in 
CO2/bicarbonate-free HEPES-buffered Tyrode’s buffer, hearts were treated with either 
EMPA or DMSO for 15 min. Intracellular [Na+] remained unchanged during this period 
in hearts treated with either 1 µM or 10 µM EMPA (Figure 5A and B). EMPA also had 
no effect on [Na+]i in mouse and guinea pig hearts, excluding a possible species-
dependent response to EMPA (Figure 5A). Together, these results suggest that 
EMPA does not affect [Na+]i handling in the isolated beating heart under physiological 
heart rates (mouse paced at 550bpm; rat 350-400 bpm; guinea pig 250-300 bpm) and 
at 37°C.  
 The effect of EMPA on beating hearts was further investigated in terms of the 
time course of pHi recovery following intracellular acidosis imposed by perfusion in 10 
mM acetate, to activate NHE1 (Figure 5C and D). Using serially acquired 31P NMR 
scans, intracellular pH was calculated from the chemical shift difference between the 
phosphocreatine (PCr) and inorganic phosphate (Pi) peak according to the 
relationship determined previously.34 To probe for pHi changes arising solely from 
NHE1, hearts were Langendorff perfused in CO2/bicarbonate-free HEPES-buffered 
Tyrode’s buffer. During 40 min of treatment in acetate, the NHE1 inhibitor cariporide 
attenuated pHi recovery following intracellular acidification (Figure 5C and D). 
However, EMPA did not inhibit this pHi recovery (1 µM, 10 µM), consistent with the 
lack of inhibitory actions of EMPA on cardiac NHE1. 
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EMPA does not affect cardiac function and energetics in Langendorff perfused 
hearts 
Left ventricular developed pressure (LVDP) was monitored by a balloon 
inserted into the left ventricle of Langendorff perfused rat hearts. Administration of 
EMPA did not affect LVDP (Figure 6A and B). The perfusion rate (i.e. a measure of 
coronary flow) that is required to maintain pressure at 80 mmHg was also not affected 
by EMPA treatment (Figure 6C and D), contrary to previous reports of a vasodilatory 
effect of SGLT2i’s.10 In contrast, cariporide reduced LVDP and coronary flow in hearts 
perfused with CO2/bicarbonate-free Tyrode’s buffer (Figure 6B and D). Cardiac 
energetics, measured in terms of the PCr/ATP ratio obtained through 31P NMR 
spectroscopy was not affected by neither EMPA nor cariporide treatment (Figure 6E 
and F).  
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5. DISCUSSION 
In this study, we present results showing that EMPA, obtained from two 
independent sources, does not inhibit NHE1 measured in terms of the two readouts of 
its activity, pHi and [Na+]i, in isolated cardiomyocytes or Langendorff-perfused beating 
hearts. We find that recovery of pHi from an intracellular acid-load was not slowed to 
any meaningful degree in the presence of EMPA up to 30 µM (Figure 1 and 2). In 
addition to EMPA, two other SGLT2i’s, DAPA and CANA, were also tested for their 
proposed inhibitory actions on NHE1 activity and found that these, like EMPA, did not 
inhibit NHE1 flux (Figure S3). As a positive control of inhibition, cariporide (10 µM) 
substantially blocked pHi recovery (Figure 1 and 2E). Intriguingly, steady-state pHi 
attained at the end of the recovery period was modestly more alkaline in 3 or 10 µM 
EMPA, compared to drug-free conditions (Figure 2G). This effect cannot be explained 
by inhibitory actions on NHE1; rather, it may relate to an inhibitory effect on 
sarcolemmal acid-loaders or changes in intracellular proton production secondary to 
changes in metabolism.  
In hearts Langendorff-perfused with CO2/bicarbonate-free Tyrode’s buffer, 
inhibition of NHE1 with cariporide (10 µM) resulted in intracellular acidification (Figure 
5C) and a reduction in LVDP (Figure 6D), consistent with the effects of acidosis on 
cardiac contractility.17,35,36 Interestingly, this effect on contractility was not evident in 
cariporide-treated hearts perfused in KHB (compare Figure 6C vs D), probably 
because the pH-regulating Na+/HCO3- co-transporter becomes activated in under 
these conditions and compensates for the loss of NHE1 activity. As the relationship 
between intracellular Na and contractility is steep,37 a ~25% fall in intracellular [Na+], 
as previously reported,9,10 might be expected to be significantly negatively inotropic. 
However, we observed no effect of EMPA on LVDP (Figure 6A and B) in Langendorff-
perfused hearts. Also, when measured directly, [Na+]i was unaffected by EMPA at 
resting pHi in isolated cardiomyocytes (Figure 3A) or in Langendorff-perfused hearts 
(Figure 5C and D). We also found no evidence that EMPA affects other Na+ entry 
pathways into the myocyte (Figure 3D). A potential effect of EMPA on Na+ extrusion 
via NKA observed in the SBFI loaded cardiomyocytes (Figure 3E) was not replicated 
in patch clamp experiments directly measuring NKA activity (Figure 4). The direct 
measurement of absolute NKA pump current (Figure 4C) also provides additional 
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article/doi/10.1093/cvr/cvaa323/5949073 by guest on 06 N
ovem
ber 2020
 17 
confirmation that EMPA did not lower [Na+]i as this current is steeply dependent on 
the intracellular Na+ concentration.33 
Prior to our study, EMPA was postulated to produce its beneficial effects on 
failing hearts by directly inhibiting cardiac NHE1 activity and thereby reducing 
intracellular [Na+].9,10 These inferences were based on measurements of pHi and [Na+] 
not dissimilar to our experiments. For example, Baartscheer et al. found that EMPA, 
obtained from MCE, at 1 µM concentration inhibited NHE1 activity by 80%, based on 
a slowing of pHi recovery after an ammonium pre-pulse.9 They also showed that EMPA 
caused a prompt ~25% decrease in [Na+]i, ostensibly due to an inhibition of NHE1-
dependent Na+ influx. These effects of EMPA were replicated in another study by the 
same group (Uthman et al.),10 who additionally found that related SGLTi (dapagliflozin 
and canagliflozin) had similar effects on pHi and [Na+]i. Independently, in silico 
mathematical simulations identified NHE1 as a target of EMPA’s cardiac actions, and 
indicated that the drug’s beneficial effects on the heart could be attributable to this 
mechanism.38 However, that study was not based on target identification experiments 
validating a direct molecular interaction between EMPA and NHE1; rather, it identified 
that an inhibition of NHE1 by EMPA would indeed be beneficial in heart failure, 
assuming that such interaction exists based on published data. 
The reasons for the discrepancy between our data and previously published 
findings are unclear. Both studies used a similar fluorimetric approach on isolated 
cardiac ventricular myocytes to measure the recovery of pHi from an acid-load 
imposed by an ammonium pre-pulse. One notable difference is that the previous 
study9 used a buffer formulation that has an inherently unstable pH, and therefore will 
drift over time. This instability is due to the inclusion of HCO3- (4.3 mM) in the absence 
of CO2, i.e. an out-of-equilibrium solution.39 In such a system, HCO3- ions will attempt 
to reach equilibrium by protonating to form CO2 (and water), but any CO2 produced 
will escape, driving the system further towards CO2 production. This has the effect of 
gradually alkalinising the solution. Since NHE1 is strongly dependent on extracellular 
pH,40 the measured NHE1 activity will not be consistent. To avoid this problem, we 
used a closed buffer system with no HCO3- and no CO2, effectively clamping buffer 
pH to 7.4. Therefore, in a buffer which contains HCO3- but not balanced by CO2, the 
time-dependence of solution pH will invariably introduce an error in measurements. 
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It is also plausible that different batches of EMPA may have varying degrees of 
purity, resulting in a lower concentration of bio-active compound in our experiments. 
To control for this, we obtained the drug from two independent sources: MCE (same 
manufacturer used in previous studies) and Boehringer. The purity and chemical 
structure of EMPA was verified using NMR, circular dichroism and HPLC-MS, and 
confirmed to be identical for both sources, and of equally high purity (<1% impurities; 
Figure S1). We also confirmed that our source of EMPA, mEMPA, DAPA and CANA 
were functionally active, as they inhibited glucose uptake in HEK293 cells 
overexpressing hSGLT2 (Figure S2). Our studies were also performed on a wider 
range of concentrations, and even at the highest dose of 30 µM (far in excess of the 
reported therapeutic range), EMPA had no meaningful inhibitory effect on NHE1. 
Another possible reason for the discrepancy could relate to species differences 
in the drug’s target, NHE1. Differences in the primary sequence of other ion 
transporters are known to affect inhibitor sensitivity. For example, in the murine heart, 
two amino acid substitutions (at positions 111 and 122 in the a1 subunit) render NKA 
resistant to ouabain when compared to other mammals (i.e. rabbits, guinea pigs, 
humans).41 Uthman et al.10 suggest that the putative binding of EMPA to NHE1 is in 
the region of the Na+ binding site and, since this is highly conserved across 
mammalian species (>90% sequence homology), there is no evidence for a species-
dependent difference in primary sequence that might alter EMPA affinity. In addition, 
there have been no reports in the literature of species-dependent differences in NHE1 
inhibitor sensitivity.42,43 Finally, the previous studies of EMPA9,10 used the same 
concentration of the drug (1 µM) for measurements on rabbit, rat and mouse hearts 
and myocytes, and produced consistent responses. In the present study, EMPA 
consistently had no actions on NHE1 in human cells (Figure S4), rat, mouse and 
guinea pig hearts (Figure 4A and B), collectively arguing against a species-
dependent difference.  
Previous in silico modelling predicted high-affinity binding of EMPA to NHE1 
involving the drug’s glucoside moiety occupying the Na+ binding site of NHE1.10 Such 
an interaction resembles that of acylguanidine-based NHE1 inhibitors, such as 
amiloride, cariporide, zoniporide, and others.44,45 The inhibitory potency of such drugs 
is related to (i) the ionization state of the acylguanidine group, which is cationic at 
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acidic pH, and (ii) structure, which resembles that of a tri-hydrated Na+ ion.29,44 A new 
class of non-acylguanidine inhibitors has been recently described (SL59122746 and 
9t47) that is predicted to bind NHE1 via their imidazole motif, a surrogate for the 
acylguanidine group.46,48 Since EMPA does not possess either of these motifs, an 
interaction with NHE1 would be surprising and certainly not canonical. 
EMPA has been shown to also inhibit SGLT1 with an IC50 of 8.3 µmol/L.1 Given 
that SGLT1 is expressed in the heart,47 it is plausible that inhibition of SGLT1 may 
have affected our results. However, evidence for the expression of this transporter 
specifically in the cardiac myocyte in healthy hearts is lacking, as localisation studies 
place it in cardiac capillaries rather than cardiomyocytes.49 In addition, of the four 
concentrations of EMPA tested in this study, two of these (1 and 3 µM) were well below 
the IC50 of SGLT1. The effect of EMPA at these lower concentrations on NHE1 flux is 
comparable to the effects observed at 10 and 30 µM EMPA, concentrations at which 
SGLT1 may be inhibited. This suggests that the lack of NHE1 inhibition by EMPA is 
independent of a possible SGLT1 inhibition (if it is indeed expressed) in cardiac 
myocytes.  
Evidence for the beneficial effects of EMPA in the heart are numerous, both in 
humans2,20,23 and in animals3–5. A number of alternative mechanisms have been 
postulated to explain the beneficial effects of SGLT2i’s in heart failure. These include 
changes in metabolic substrate preference and more efficient mitochondrial energy 
production,50,51 and improved ventricular loading secondary to enhanced renal 
function.52,53 Recently, it was also shown that EMPA can increase nitric oxide (NO) 
signalling in the heart.54 However, based on the results of this study, the observed 
cardioprotective effects cannot be explained by a direct inhibitory interaction of SGLT2 
inhibitors, especially EMPA, with cardiac NHE1 and subsequent lowering of 
intracellular [Na+].  
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11. FIGURE LEGENDS 
Figure 1: EMPA does not inhibit NHE1 activity in isolated cardiomyocytes. pHi 
recovery time course (A), (C), (E), (G) and NHE1 flux as a function of pHi (B), (D), (F), 
(H) measured in rat ventricular cardiac myocytes exposed to acute NH4+ acid load 
and wash-out and pre-treated with DMSO, 10 µM cariporide or 1 or 10 µM EMPA 
obtained from MedChemExpress (mEMPA; yellow) or Boehringer (EMPA; red). Flux 
is calculated from rate of pHi change (from time courses) multiplied by buffering 
capacity (obtained in previous studies). Note: in the presence of cariporide, pHi 
recovery is not complete in 12 min, and the flux is therefore only plotted for pH<6.9. 
N.T. = Normal Tyrode’s buffer. All data means ± SEM (error bar not included in (A), 
(C), (E), and (G) for clarity). n = 14-20 cells from 3 rats per condition. 
Figure 2: EMPA does not inhibit NHE1 flux in isolated cardiomyocytes. (A-E) 
Acid extrusion flux (JH; mM/min) plotted at matching pHi for control (DMSO) and in 
presence of drug (EMPA or cariporide) at the concentrations indicated. Red or blue 
lines show best fit through origin, and the slope describes NHE1 activity in the 
presence of drug (where 1.0 is no inhibition, indicated in broken black line). (F) Slope 
of flux-flux relationships for EMPA, DAPA, CANA and cariporide (Carip.). (G) Steady 
state pHi attained at the end of pH recovery. All data are means ± SEM; means ± 95% 
confidence interval for (F). Data from EMPA and mEMPA were combined. For EMPA 
and cariporide, n = 30-49 cells from 3 rats per condition. For DAPA and CANA, n = 
31-43 cells from 2 rats per condition. * p<0.05 by one-way ANOVA. 
Figure 3: EMPA does not affect intracellular Na+ handling in isolated 
cardiomyocytes. Intracellular [Na+] measured using SBFI fluorescence in myocytes 
treated with DMSO, 1 µM or 10 µM EMPA or 10 µM cariporide (A) at baseline or (B) 
in 80 mM Na-acetate. Ratio corrected for pH-artefact (Rx1.04), marked by double line 
at 15 min. See Figure S2 for original time course. n = 24-33 cells from 3 rats per 
condition. (C) Interrogation of NHE1-independent Na+ transport pathways using 
0Na0Ca protocol. Time constant of (D) Na+ re-uptake and (E) Na+ efflux. All data are 
means ± SEM (error bar not included in (B) and (C) for clarity). n = 24-30 cells from 3 
rats per condition. ** p<0.01 by two-tail, unpaired student’s t-test. 
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Figure 4: EMPA does not affect Na+/K+ ATPase current in isolated cardiomyocytes.  
Whole-cell pump current was measured using the perforated patch-technique in rat 
ventricular myocytes. (A) Representative trace showing pump current (Ip) recorded under 
control conditions and after the application of EMPA (10 µM). Pump current was recorded 
at 0 mV. Potassium-free bath solution was applied at the points shown (K+-free). (B) 
Current-voltage relationships recorded during the application of a negative-going voltage 
ramp (13 mV/sec) under control conditions and after application of EMPA. Data were 
averaged (factor 800) to obtain ~1 reading every 5 mV and normalized to the current 
reading at 0 mV. (C) Average Na+/K+ ATPase current density recorded after 300 s in 
control and EMPA.  All data are means ± SEM. n = 6 cells from 6 rats.  
Figure 5: EMPA does not affect intracellular [Na+] and pHi in Langendorff-
perfused hearts. Intracellular [Na+] measurement using 23Na NMR spectroscopy in (A) 
rat, mouse and guinea-pig hearts perfused in CO2/bicarbonate-buffered KHB and 
treated with 1 µM EMPA and (B) rat hearts perfused with CO2/bicarbonate-free 
Tyrode’s buffer and treated with either 1 or 10 µM EMPA. n = 6 rats (A and B), 6 mice 
(A and B), and 2 guinea pigs (A) per group; 23Na signal normalised to baseline. Rat 
hearts pre-treated with DMSO (open circle), 10 µM cariporide (blue square), (C) 1 µM 
or (red triangle) (D) 10 µM EMPA (red, open diamond), and perfused in Tyrode’s buffer 
supplemented with 10 mM Na-acetate. Intracellular pH measured using 31P NMR 
spectroscopy. All data mean ± SEM. n = 6 rats per group per assay. 
Figure 6: EMPA does not affect cardiac contractile function and energetics in 
Langendorff perfused rat hearts. (A) and (B) Left ventricular developed pressure 
(LVDP) measured using balloon inserted into left ventricle of rat heart. (C) and (D) 
Coronary flow required to maintain perfusion pressure at 80 mmHg. DMSO control 
(open circle), 10 µM cariporide (blue square), 1 µM EMPA (red triangle) or 10 µM 
EMPA (red, open diamond). (E) and (F) PCr/ATP ratio measured using 31P NMR 
spectroscopy. Hearts perfused in Kreb’s buffer (KHB) (A), (C), and (E) and in 
CO2/bicarbonate-free HEPES-buffered Tyrode’s (Tyrode) (B), (D), and (F). All data 
mean ± SEM. n=6 rats (KHB) or 5 rats (CO2/bicarbonate-free Tyrode) per group. *** 
p<0.001 by two-way ANOVA.  
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